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Abstract
Background: In cultured prostate cancer cells, down-regulation of epidermal growth factor receptor (EGFR) has been
implicated in mediating the antiproliferative effect of the endogenous cannabinoid (CB) ligand anandamide. Using a well-
characterised cohort of prostate cancer patients, we have previously reported that expression levels of phosphorylated
EGFR (pEGFR-IR) and CB1 receptor (CB1IR) in tumour tissue at diagnosis are markers of disease-specific survival, but it is not
known whether the two markers interact in terms of their influence on disease severity at diagnosis and disease outcome.
Methodology/Principal Findings: Data from a cohort of 419 patients who were diagnosed with prostate cancer at
transurethral resection for voiding difficulties was used. Scores for both tumour CB1IR and pEGFR-IR were available in the
database. Of these, 235 had been followed by expectancy until the appearance of metastases. For patients scored for both
parameters, Cox proportional-hazards regression analyses using optimal cut-off scores indicated that the two measures
provided additional diagnostic information not only to each other, but to that provided by the tumour stage and the
Gleason score. When the cases were divided into subgroups on the basis of these cut-off scores, the patients with both
CB1IR and pEGFR-IR scores above their cut-off had a poorer disease-specific survival and showed a more severe pathology at
diagnosis than patients with high pEGFR-IR scores but with CB1IR scores below the cut-off.
Conclusions/Significance: These data indicate that a high tumour CB1 receptor expression at diagnosis augments the
deleterious effects of a high pEGFR expression upon disease-specific survival.
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Introduction
The endogenous cannabinoid (CB) system in the body consists
of two G-protein coupled CB receptors, CB1 and CB2, their
endogenous ligands anandamide (arachidonoylethanolamide) and
2-arachidonoylglycerol, and their synthetic and degradative
enzymes. Whilst much is known about the role of the
endocannabinoid system in the brain and its potential for the
design of novel analgesic drugs, among others, evidence is
emerging that it may play an important role in the pathogenesis
and possibly treatment of cancer [1-3]. In prostate cancer cells, for
example, activation of CB receptors usually [4–8] but not
invariably [9] leads to inhibition of basal and/or stimulated cell
proliferation. An increase in the local endocannabinoid concen-
tration (by blockade of their metabolism) results in a reduced
invasivity of the cells in vitro, whilst reduction of 2-arachidonoyl-
glycerol synthesis, blockade of CB1 receptors, or an increased
expression of the anandamide metabolising enzyme fatty acid
amide hydrolase produces the reverse pattern [10,11]. Taken
together, these studies suggest that in the prostate, there is a local
protective endocannabinoid tonus. Consistent with this hypothesis,
expression of epithelial fatty acid amide hydrolase, the enzyme
responsible for the metabolism of anandamide, is higher in
prostate cancer tissue than in normal prostate tissue, and
transfection of androgen-insensitive PC3 prostate cancer cells
increases their invasivity in vitro [12].
The epidermal growth factor receptor (EGFR) is a cell surface
receptor tyrosine kinase responsive to a number of growth factors,
including epidermal growth factor, transforming growth factor a
and amphiregulin. Phosphorylation of EGFRs leads to activation
of a number of different intracelluar signalling pathways, in turn
resulting in cell growth and survival [13]. Disturbed EGFR
signalling, due for example to the overexpression of EGFR, is
involved in the pathogenesis of several cancer types, and
antibodies directed towards the extracellular domain of EGFR
have been developed for the treatment of cancers such as
advanced colorectal cancer [13,14]. In the prostate, higher levels
of epithelial EGFR immunoreactivity (EGFR-IR) were seen in
prostatic adenocarcinoma than in normal tissue [15], and patients
with a tumour tissue pEGFR-IR score in the top 66% bracket
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15205showed a poorer disease-specific survival than those cases with a
pEGFR-IR score in the bottom 34% [16].
Very little is known about the link between cannabinoid and
EGFR signalling in cancer, and nothing is known in this respect in
human tumour tissue. To our knowledge, the only study
undertaken in prostate cancer cells is that reported by Mimeault
et al. [5]. These authors found that anandamide inhibited EGF-
stimulated cell proliferation of LNCaP, DU145 and PC3 prostate
cancer cells in a manner blocked by pertussis toxin (implicating a
Gi-coupled receptor) and by the CB1 receptor inverse agonist
rimonabant, but not by the CB2 receptor inverse agonist
SR144528. Furthermore, in all three cell lines, anandamide
treatment reduced the expression of EGFR, again in a manner
blocked by rimonabant [5]. Given the local protective role of
endocannabinoids in the prostate (see above), this study raises the
possibility that differences in the relative expression of CB1
receptors and pEGFR in the tumour tissue may affect the
pathogenesis and outcome of the disease.
At Umea ˚ university, we have access to a large series of formalin-
fixed, paraffin-embedded samples of prostate tumour and non-
malignant tissue that were obtained at diagnosis from patients
undergoing transurethral resection for micturation difficulties. The
patients were followed for up to 23 years, in many cases by active
expectancy (watchful waiting) until the appearance of metastases,
this being the treatment paradigm at the time [17]. This material
allows the study not only of the association of biochemical
parameters with disease severity at diagnosis, but also of their
association (and potential prognostic usefulness) with disease-
specific survival. These samples were used for the tumour
epithelial pEGFR study described above [16], but have also been
used by us to investigate CB1 receptor immunoreactivity (CB1IR)
in prostate cancer, where a high tumour expression level was
associated with a poorer disease-specific survival [18]. Thus, both
parameters were measured in the same patient set, and in a simple
correlation matrix, we noted that tumour epithelial pEGFR and
CB1IR were significantly correlated [19]. However, it is not known
whether the two parameters provide additive or alternatively
overlapping prognostic information, and whether cases with
different levels of CB1IR for a given pEGFR-IR show different
degrees of disease severity upon diagnosis. In consequence, we
have reanalysed the raw data from [16] and [18] to answer these
questions.
Methods
Ethics Statement
The research ethical committee at Umea ˚ university hospital
(Regional Ethical Review Board in Umea ˚, Sweden) approved of
the studies and waived the need for informed consent.
Patient material and immunochemistry
The tumour epithelial CB1IR and pEGFR-IR scores used in the
present study were taken from our database, the original data for
CB1IR and pEGFR-IR having been published previously [16,18].
Readers are referred to those papers for a detailed description of
the samples and immunohistochemical techniques used. The tissue
material was collected at the Regional Hospital, Va ¨stera ˚s, Sweden,
between 1975 and 1991, and the patients were followed until
2003. Tissue microarrays were constructed and in general between
1 and 8 cores (usually 5) (tumour tissue) and 1–4 cores (non-
malignant tissue) could be scored for the parameter in question.
CB1IR was scored on the basis of intensity (0= absent up to 3=
high intensity) 6distribution, giving a range of 0–3. The median
value for the cores scored for a given patient were then entered
into the database. pEGFR was also scored on the basis of intensity
and distribution, but in this case the range was 0–5. In both cases,
the scores were provided by investigators who were blind to the
patient data.
Statistical evaluations
Receiver operating characteristic (ROC) curves, Kaplan-Meier
survival analyses, correlation coefficients and x
2 tests were
undertaken using the statistical package built into the GraphPad
Prism 5 computer programme for the Macintosh (GraphPad
Software Inc., San Diego, CA, USA). Cox proportional-hazards
regression analyses, were conducted using SPSS software (SPSS
Inc., Chicago, IL, USA). For survival analyses, an event was
defined as death due to prostate cancer (shown in the figures as
‘‘{p’’). Death from other causes was censored, as were the cases
where the patient was still alive at the date of last follow-up. Cases
(n=3) where the disease outcome was unknown were excluded
from the survival analyses. The duration of event-free survival is
defined as the time from diagnosis until either the date of prostate
cancer death, death of other causes, or if no death occurred, until
the date of last follow-up.
Results
Correlation of CB1IR and pEGFR-IR in prostate cancer
samples
Out of a total of 419 cases in the database, 372 were scored for
tumour CB1IR [18] and 300 for tumour pEGFR-IR [16]. The
CB1IR scores ranged from 0–3 units (median 2) and the pEGFR-
IR scores from 0-5 units (median 3.3). The significant correlation
between tumour CB1IR and the tumour pEGFR-IR in the 280
cases where both parameters were scored (Spearman’s r=0.316,
p,0.001) found in our initial investigation, and which sparked the
present analysis [19], can simply be visualised by dividing the
pEGFR-IR scores into quadrants and comparing the CB1-IR at
each score (Fig. 1). Non-malignant CB1IR was also correlated with
the non-malignant pEGFR-IR (r=0.183, p,0.01 for luminal
pEGFR and r=0.159, p,0.01 for basal pEGFR, n=264).
Figure 1. Distribution of CB1IR scores for different pEGFR
scores in prostate tumour tissue. The pEGFR scores were divided
into quadrants (1st, pEGFR ,2.6, n=68; 2nd, 2.6–3.29, n=68; 3rd 3.3–
3.7, n=75; 4th, .3.7, n=69) and the CB1IR score at each quadrant
shown. The number of cases with CB1IR scores ,2, 2 [the median value]
and .2 were 73, 93 and 114, respectively. ***p,0.001, x
2 test.
doi:10.1371/journal.pone.0015205.g001
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Of the patients recorded in the database, 307 had been
followed with expectancy until the development of metastases
rather than being given a curative treatment, this being the
standard therapeutic approach at the time. These patients
provide a useful resource with which to assess the prognostic
value of biomarkers. Of these, 269, 253 and 235 were scored for
tumour CB1IR, tumour pEGFR-IR and both parameters,
respectively, cases where patient outcome was not known having
been excluded.
A standard way of assessing the prognostic utility of a biomarker
is to use a receiver operating characteristic (ROC) analysis. ROC
analyses were originally developed to aid the interpretation of
radar signals, and plot the number of true negatives (termed ‘‘1-
specificity’’) vs. the number of true positives (termed ‘‘sensitivity’’)
for all the possible cut-off values for the data set. The area under
the curve (AUC) of the resulting graph will be somewhere between
0.5 (no prognostic value) and 1.0 (a perfect test) [20–22]. The
ROC curves, with a 15 year cut-off, for tumour CB1IR and
pEGFR-IR values (only cases scored for both CB1IR and pEGFR-
IR were included in the analyses) are shown in Fig. 2. As expected
from our original data [16,18], the AUC for both CB1IR and
pEGFR were significantly greater than 0.5.
Having obtained a ROC curve with an area under the curve
significantly greater than 0.5, a cut-off can then be chosen for
which to investigate the influence of the biomarker upon disease-
specific survival. The choice of cut-off is a trade-off between the
cost (in terms of discomfort to the patient) of treating false positives
(the number of which increase as the cut-off value decreases) with
that of missing false negatives (the number of which increase as the
cut-off value increases) [20–22]. In our initial studies, we used cut-
off values of , and $2 (for CB1IR) and , and $2.78 (for pEGFR)
were used, since these values were the lowest scores giving a
specificity .0.5 [16,18]. However, when investigating the
interaction between two potential prognostic markers, the most
appropriate cut-off value is the optimal value for each parameter
in question, i.e. the point nearest the top left of the graph shown in
Fig. 2. The two methods most commonly used to quantify the
optimal cutoff are the least squares method (minimum value of (1-
sensitivity)
2 + (1-specificity)
2) and the Youden index (the maximum
score of (specificity + sensitivity -1)). The two methods give
identical cut-offs in some cases, but not in others [22]. In the case
of pEGFR, both methods gave an optimal cut-off of .3.172
(shown as the blue arrow in Fig. 2), i.e. division of the samples into
two groups with scores ,3.2 and $3.2 In the case of CB1IR, the
Youden index (red arrow in Fig. 2) was .2.275, i.e. division of the
samples into two groups with scores ,2.3 and $2.3, whilst for the
least squares method, the cut-off was slightly lower (.2.088, grey
arrow in Fig. 2). It has been argued that the Youden index is more
appropriate in a clinical setting than the least squares method [22]
and we have in consequence used the Youden index here for our
further analyses. Division of the samples into test and validation
sets with which to test the prognostic usefulness of the markers
gave the same Youden index values (see supporting Fig. S1 and
legend for the data with CB1IR).
In survival analysis, Cox proportional-hazards regressions are
used to assess the contribution of different prognostic markers
upon the measured end-point (here death due to prostate cancer)
without making assumptions about the shape of the survival curve.
Here, we used Cox proportional-hazards regression analyses to
establish whether or not the tumour CB1IR provided additional
prognostic information to that supplied by pEGFR-IR (Table 1).
Using the optimal cut-off values determined in the ROC analyses,
we found this to be the case, and the two parameters also gave
additional prognostic information to that supplied by the tumour
stage and the Gleason score.
In order to visualise the importance of these findings, survival
curves were constructed for the 235 cases scored for both pEGFR-
IR and CB1IR. The data was divided into four subsets on the basis
of the pEGFR-IR and CB1IR scores. The Groups are termed Ia
(n=101), Ib (n=7), IIa (n=98) and IIb (n=29), where I and II
refer to the pEGFR-IR (,3.2 and .3.2, respectively) and a and b
refer to the CB1IR scores. Thus, for example, Group Ia consists of
cases where both scores are below their respective Youden cut-offs
whilst Group IIb represents the other extreme, where both scores
are above the respective Youden cut-offs. The very low incidence
of cases in Group Ib (low pEGFR-IR, high CB1IR) means that the
survival curves for this group are much less robust than for the
other groups. Nonetheless, a clear pattern emerged, consistent
with the COX regression analyses, where the disease-specific
survival was best for the Group Ia cases and poorest for the Group
IIb (and possibly also Group Ib) cases (Fig. 3A). The 15 year
Figure 2. Receiver operating characteristic (ROC) curves for tumour CB1IR and pEGFR-IR. For each curve, the number of cases used in the
analysis (which used a 15 year limit) together with the mean AUC value is shown. Values in square brackets are the 95% confidence intervals for the
AUCs. {p refers to the number of cases who died as a result of the prostate cancer. The arrows show the part of the curve corresponding to the
optimal cut-off values: red = Youden index for CB1IR, grey = least squares method for CB1IR, blue = both Youden and least squares method for
pEGFR-IR (for details, see Results section of this paper).
doi:10.1371/journal.pone.0015205.g002
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5467% and 766%, respectively. The corresponding value for
Group Ib was 22619%, the large s.e.m. value reflecting the small
sample size. The pattern whereby a high CB1IR augmented the
effect of a high pEGFR-IR (i.e. Groups IIa vs IIb) was also seen
when the data was restricted to subsets of cases with tumour stage
T2 (Fig. 3B), Gleason scores 6–7 (Fig. 3C), and 8–10 (Fig. 3D).
Comparisons for other subgroups are limited either by too few
events (Gleason scores 4–5, tumour stage T1a–T1b) or small
group sizes (Tumour stage T3 and T4) and are in consequence not
shown here.
A high CB1IR augments the effect of a high pEGFR upon
disease severity at diagnosis
In view of the finding that the CB1IR provided additional
prognostic information to that of pEGFR, the pattern of disease
severity at diagnosis was investigated for all 280 patients scored for
both parameters. Again, the number of cases in Group Ib was low
(n=8). Nonetheless, for the four markers of disease severity
investigated (Gleason score, tumour stage, incidence of metastases
at diagnosis and the percent of the specimen that contained
tumour, there was a clear influence of the CB1IR/pEGFR Group
upon the observed pattern, with the Group IIb cases having the
most severe pattern (Fig. 4). For two of the four measures, the
Group IIb cases had a more severe pattern than the Group IIa
cases, suggesting that the deleterious influence of a high pEGFR
expression in the tumours is further augmented by a high CB1
expression.
Discussion
In the present study, we have reanalysed previously published
data [16,18] to determine how the expression of prostate tumour
epithelial CB1 receptors affects disease severity and outcome in
patients with different tumour expression levels of pEGFR. In this
discussion, three questions are addressed:
1. What was known prior to the analyses and what is
novel?
We had previously reported that both CB1IR and pEGFR-IR
are associated with disease severity at diagnosis and with disease-
specific survival [16,18] and that the two measures are correlated
[19]. This correlation might have meant that the two markers act
simply as alternative prognostic markers and that the utility of one
in a diagnostic test would not be improved by the addition of the
second marker. In fact, the present study shows that they provide
additive diagnostic information, which may be useful indeed.
2. What are the implications of the study for disease
mechanisms?
The simplest way to consider the implications of the present
study is to consider cancer cells that are susceptible to the
deleterious effects of CB receptor activation and those that are not.
In susceptible cell lines from several different cancer types,
activation of CB receptors leads to a variety of different cellular
events, including the sustained production of ceramide, reduced
expression of vascular endothelial growth factor and matrix
Table 1. Cox proportional-hazards regression analyses for tumour epithelial CB1IR and pEGFR-IR scores.
Variable n Exp(B) 95% CI Variable N Exp(B) 95% CI
Univariate analyses Bivariate analysis
CB1IR ,2.3 225 CB1IR ,2.3 199
$2.3 44 4.40*** 2.69–7.21 $2.3 36 3.75*** 2.24–6.29
pEGFR ,3.2 108
pEGFR ,3.2 108 $3.2 127 3.01*** 1.61–5.61
$3.2 127 3.85*** 2.09–7.08
Multivariate analysis
T
a T1a–T1b 162 CB1IR ,2.3 198
T2 71 3.66*** 2.03–6.58 $2.3 36 2.64** 1.53–4.58
T3 31 11.2*** 5.86–21.3 pEGFR ,3.2 108
T4 3 10.7* 1.40–81.5 $3.2 126 2.10* 1.12–3.94
T
a T1a–T1b 142
GS
b 4–5 78 T2 60 1.38
NS 0.70–2.73
6–7 132 22.7** 3.1–166 T3 29 2.86** 1.33–6.17
8–10 59 139*** 18.9–1020 T4 3 4.87
NS 0.62–38.2
GS
b 4–5 48
6–7 130 13.4* 1.80–99.2
8–10 56 46.6*** 6.04–360
Analyses were carried out using data (reported in [16] and [18]) from patients who were followed by expectancy until the appearance of metastases.
aTumour stage,
bGleason score (in both cases, as well as for pEGFR, the sample sizes used in the univariate analyses are for those which were scored for CB1IR). Exp(B) refers to the
increase in the odds as a result of an increase in the ‘‘unit’’ of the predictive variable under study.
***p,0.001,
**p,0.01,
*p,0.05,
NSp.0.1.
doi:10.1371/journal.pone.0015205.t001
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signal-related kinase 1/2, resulting in apoptosis, inhibition of
tumour adhesion, migration and angiogenesis [2,23,24]. In vitro
studies undertaken in cell lines together with data from tissue
microarrays are consistent with the proposal that a local
endocannabinoid tonus controls the invasivity of prostate cancer
cells [10–12,19] (see introduction). In this respect, the endocanna-
binoid system can be considered as a ‘‘damage limiter’’ not only in
prostate cancer [10–12], but in other potentially harmful
situations, such as following tissue damage [25]. This ‘‘damage
limitation’’ may also occur in some other solid tumours, given than
in hepatocellular cancer, a low CB1 receptor expression impacts
negatively upon survival [26], and that in colorectal cancer, a loss
of CB1 receptors due to hypermethylation of the CB1 receptor
promotor region has been reported [27]. However, such ‘‘damage-
limitation’’ can be negated by overexpression of other pathways
promoting cell proliferation and survival. The EGFR receptor is
coupled to a number of intracellular signalling systems, such as the
Ras/Raf/MAPK and PI3K/Akt pathways, which induce cell
proliferation, migration and resistance to apoptosis [13,14]. In rat
C6 glioma cells, the level of expression of the EGFR ligand
amphiregulin is a factor determining the degree of resistance of the
cells to the deleterious effects of cannabinoids [28]. Extrapolating
this finding to the prostate (with all the appropriate caveats
concerning different cancer cell types and the large step between
cultured cells and tumour tissue), it can be argued that
overexpression of EGFR ligands, the EGFR receptor itself, and/
or the level of EGFR activation would work against the local
protective endocannabinoid tone. Certainly, this would be
consistent both with the in vitro study showing that anandamide
down-regulates EGFR [5], and may contribute to some extent to
the more severe form of the disease seen at diagnosis for patients
with a high pEGFR-IR (Fig. 4, comparison between Groups Ia
and IIa). With respect to disease-specific survival, there is clearly
an effect of the pEGFR for the entire data set (Table 1, Fig. 3A),
although this is not seen for the Gleason group 6–7 and the
tumour stage 2 cases.
The observation in the present study that a high, rather than a
low, CB1IR compounds the effect of pEGFR upon disease severity
and outcome is at first sight rather difficult to explain, since a high
CB1 receptor expression would be expected to be protective,
rather than damaging. However, an attractive explanation can be
Figure 3. The influence of pEGFR-IR and CB1IR scores upon disease-specific survival of patients with prostate cancer. Panel A, all
cases; B, cases with tumour stage 2; C, cases with Gleason scores of 6 or 7; D, cases with Gleason scores of 8–10. Scores are shown as CB1IR/pEGFR
Group Ia (pEGFR-IR ,3.2, CB1IR ,2.3), Group IIa (pEGFR $3.2, CB1IR ,2.3), Group Ib (pEGFR-IR ,3.2, CB1IR $2.3) and Group IIb (pEGFR $3.2, CB1IR
$2.3). {p refers to the number of cases who died as a result of the prostate cancer. The x
2 values shown in the panels are from the log rank (Cox-
Mantel) test. Individual comparisons between two groups were also undertaken. The symbols given between the capped line in the figure itself
indicate a comparison (log rank (Cox-Mantel) test) for Group IIa vs. Group IIb (i.e. between the blue and dark red survival curves), whilst the symbols
between the capped lines in the legends indicate significance levels for the comparisons shown. When the group size was #5, the curves are shown
in a lighter colour, and whilst the data were included in the total x
2 statistic (bottom left in Panels A–C, top right in Panel D), individual comparisoms
were not undertaken. ***p,0.001, **p,0.01, *p,0.05,
NSp.0.2. In no case were the median pEGFR-IR scores in the Groups IIa and IIb significantly
different from each other (p.0.4, Mann-Whitney U-test).
doi:10.1371/journal.pone.0015205.g003
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where the responsiveness to cannabinoids was found to be
dependent upon the expression level of CB receptors. These
authors showed at low levels of CB receptor expression, the
predominant signalling pathway was via Erk1/2, and cannabi-
noids produced apoptosis, whilst at high levels of expression, a
second signal transduction pathway via Akt (a survival pathway)
became predominant, and the ability of cannabinoids to produce
apoptosis was lost, unless Akt signalling was blocked concomitantly
[29]. Taken together, these data would suggest that the ability of
endocannabinoids to act as a local regulator limiting the spread of
cancer cells would be replaced by a pro-survival effect of these
local mediators at high rates of receptor expression. A mitogenic
effect of cannabinoids in LNCaP cells has been reported [9] and it
is possible that this may also be related to the level of expression of
CB receptors in the cells under the conditions used. This
hypothesis is admittedly based on work with cultured cells, but
would explain why a high expression of CB1 receptors is associated
with a poor disease-specific survival in both prostate cancer [18]
and pancreatic cancer [30]. In such cases, a high CB1 receptor
expression would compound the deleterious (and non-CB1
receptor-related) effects produced by a high EGFR activity. A
high expression of phosphorylated Akt (pAkt-1) is associated with a
poorer recurrence-free survival in prostate cancer [31], and it
would clearly be of interest to investigate whether the expression of
CB1 receptors is correlated with pAkt-1 in prostate tumour tissue
obtained at diagnosis. Additionally, it would be of interest to
determine in cultured cells expressing high levels of CB1 receptors
whether activation of these receptors results in an increased
phosphorylation of EGFR, since this would provide an explana-
tion for the low incidence of cases with a high CB1IR/low
pEGFR-IR in the present study.
3. Do CB1IR and pEGFR-IR have diagnostic potential?
We have previously argued that the pEGFR score may be a
useful measure to aid treatment decisions for patients with Gleason
scores 6 or 7 [16]. The present study would condition that
conclusion somewhat, suggesting that the CB1IR is of considerable
importance. This is particularly true for the entire data set, where
the 15 year disease-specific survival for patients with low pEGFR-
IR and CB1IR scores (Group Ia) is very favourable (8565%). In
contrast, patients with high expressions of the two parameters
(Group IIb) had a very poor 15 year disease-specific survival
(766%), with patients with a high pEGFR-IR and a low CB1IR
(Group IIa) being intermediate (5467%). This, together with the
fact that the two measures provide additional prognostic
information not only to each other but importantly to that given
by the Gleason scores and the tumour stage (Table 1) raises the
possibility that they may have useful diagnostic value in aiding
treatment decisions, the proviso, of course, being that other
Figure 4. Effects of the tumour CB1IR and pEGFR scores upon the severity of the disease at diagnosis. Shown are: A, tumour stage (T); B,
Gleason scores (GS); C, absence (M0) or presence (M1) of metastases at diagnosis; and D, the % of the specimen that was contained tumour (%Ca). For
definition of the CB1IR/pEGFR-IR groups, see Legend to Fig. 3. The x
2 statistic for the total data set is given in each panel under the explanatory
legends. The symbols between the capped lines above the bars indicate significance levels for the individual comparisons shown. ***p,0.001,
#p,0.1, NS, p.0.2, x
2 test or Fisher’s exact test (when comparisons were for a 262 matrix).
doi:10.1371/journal.pone.0015205.g004
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and with different (but equally well validated) antibodies.
However, a practical hinder to their use is that the scores are a
composite of immunoreactive intensity and distribution, which
may be cumbersome in a clinical setting. What needs to be
determined is the extent to which the scores can be simplified
without losing their diagnostic power. We have started to
investigate this with respect to the CB1IR, and found that
reanalysis of selected cores for each case using predominant
intensity as a measure instead of the composite score does retain
some of its diagnostic power (association with disease severity and
outcome, as well as its ability to provide added diagnostic
information to that provided by the tumour stage), whereas its
ability to provide added diagnostic information to that provided by
the Gleason score is lost (C.J. Fowler, unpublished findings).
However, given the clear influence of pEGFR-IR and CB1IR
upon disease severity and outcome, studies optimizing these
markers for clinical use are clearly warranted.
Supporting Information
Figure S1 CB1IR as a prognostic factor. A useful way to
assess the prognostic value of a biomarker is to select a cut-off
value from a data subset and then validate it using a separate data
subset (see [16] for an example with pEGFR). Here, the 419
original cases were assigned a random number (using different
random sets for CB1IR and pEGFR-IR) and the untreated
patients in the random number set 1-279 and 280-419 were used
as the test and validation sets, respectively. Panel A shows the
ROC curve (using a 15 year limit) for CB1IR in the test set, from
which the optimal cutoff (Youden index, shown as an arrow in the
figure) at .2.3, i.e. the same as for the complete data set (see
Results), was chosen. Panels B and C show Kaplan-Meier plots for
the test set and validation set, respectively. {p refers to the number
of cases who died as a result of the prostate cancer. The x
2 values
shown in the panels are from the log rank (Cox-Mantel) test. Thus,
the survival curves for both the test and the validation sets using
these cut-offs confirmed the prognostic value of CB1IR.
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